Jeremy Kirk: h-index, Total Citations, and Citation Map
Jeremy Kirk's h-index is 46 (109 i10-index, 11,648+ total citations across 5+ publications) according to Google Scholar as of May 2026. Jeremy Kirk is affiliated with Unknown affiliation.
Jeremy Kirk is a researcher affiliated with Unknown affiliation, specializing in various fields. Their work has been cited 11,648 times. This profile visualizes their global influence, highlighting strong citation networks in United States.
Jeremy Kirk's Citation Metrics
Bibliometric impact based on 5 indexed publications.
- H-Index
- 46
- i10-Index
- 109
- Total Citations
- 11,648
- Citing Countries
- 10
As of May 2026.
Jeremy Kirk has an h-index of 46 and 11,648 total citations across 5 publications, with research cited by institutions in 10 countries.
Download Exports (PNG, CSV, Poster)
Free Viewing Jeremy Kirk's citation map is always free. Pay once to download poster, PNG, and CSV files for offline use or your visa packet.
We've mapped 5,000 of 11,648 citations for Jeremy Kirk
We've shown the most-cited 5,000. Unlock the full crawl (11,637 more citations) to see every institution citing this scholar.
Global Impact Map
Visualizing the geographic distribution of institutions that have cited your work.
Starting…
Pins will appear here as institutions are resolved — no need to refresh.
Top Cited Works
Tip: clickto hide a row from the map
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
20213,005
Top Citing Countries
Top Citing Institutions
Visa Evidence Package
Views and exports tuned for EB-1A, O-1A, and EB-2 NIW petitions. Sustained acclaim, geographic reach, and independent-citation filtering are the strongest evidence categories immigration adjudicators look for.
Significant Contributions
Auto-detected research lines — a seminal paper and the follow-up work building on it. Review and edit before using in a petition. Each Free PDF opens in a new tab — EB-1A organises this into the structure USCIS applies to Criterion 5 of 8 CFR § 204.5(h)(3)(v); EB-1B re-frames it under § 204.5(i)(3) (outstanding researcher); NIW presents it under prong 2 of Matter of Dhanasar.
The researcher conducted a pivotal randomized controlled trial establishing the efficacy of tocilizumab for hospitalized COVID-19 patients, generating substantial independent scholarly impact.
The researcher established a critical link between Sox2 mutations and hypothalamo-pituitary-gonadal axis abnormalities, providing foundational insights into reproductive development disorders in both mice and humans.
The researcher contributed to the clinical evaluation of casirivimab and imdevimab for hospitalized COVID-19 patients through a major randomized, controlled, open-label platform trial.
Citation trend (last 10 years)Click to expand
Citation Trend (Last 10 Years)
Related Guides
Learn how to use citation maps for your research and visa applications.
